Mostrar el registro sencillo del ítem

dc.contributor.authorJacobsson, Susanne
dc.contributor.authorCole, Michelle J
dc.contributor.authorSpiteri, Gianfranco
dc.contributor.authorDay, Michaela
dc.contributor.authorUnemo, Magnus
dc.contributor.authorEuro-GASP Network
dc.contributor.authorVazquez-Moreno, Julio Alberto 
dc.contributor.authorAbad, Raquel 
dc.date.accessioned2022-09-19T07:35:25Z
dc.date.available2022-09-19T07:35:25Z
dc.date.issued2021-03-18
dc.identifier.citationBMC Infect Dis. 2021 Mar 18;21(1):273.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14990
dc.description.abstractBackground: The emergence and spread of antimicrobial resistance (AMR) in Neisseria gonorrhoeae, nationally and internationally, is a serious threat to the management and control of gonorrhoea. Limited and conflicting data regarding the epidemiological drivers of gonococcal AMR internationally have been published. We examined the antimicrobial susceptibility/resistance of gonococcal isolates (n = 15,803) collected across 27 European Union/European Economic Area (EU/EEA) countries in 2009–2016, in conjunction to epidemiological and clinical data of the corresponding patients, to elucidate associations between antimicrobial susceptibility/resistance and patients’ gender, sexual orientation and anatomical site of infection. Methods: In total, 15,803 N. gonorrhoeae isolates from the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), 2009–2016, were examined. Associations between gonococcal susceptibility/resistance and patients’ gender, sexual orientation and anatomical site of infection were investigated using univariate and multivariate logistic regression analysis. Statistical significance was determined by Pearson χ 2-test or Fisher’s exact test with two-tailed p-values of < 0.05 indicating significance Results: The overall gonococcal resistance from 2009 to 2016 was 51.7% (range during the years: 46.5–63.5%), 7.1% (4.5–13.2%), 4.3% (1.8–8.7%), and 0.2% (0.0–0.5%) to ciprofloxacin, azithromycin, cefixime, and ceftriaxone, respectively. The level of resistance combined with decreased susceptibility to ceftriaxone was 10.2% (5.7–15.5%). Resistance to cefixime and ciprofloxacin, and resistance combined with decreased susceptibility to ceftriaxone were positively associated with urogenital infections and heterosexual males, males with sexual orientation not reported and females (except for ciprofloxacin), i.e. when compared to men-who-have-sex-with-men (MSM). Azithromycin resistance was positively associated with heterosexual males, but no association was significant regarding anatomical site of infection. Conclusions: Overall, sexual orientation was the main variable associated with gonococcal AMR. Strongest positive associations were identified with heterosexual patients, particularly males, and not MSM. To provide evidence-based understanding and mitigate gonococcal AMR emergence and spread, associations between antimicrobial susceptibility/resistance and patients’ gender, sexual orientation and anatomical site of infection need to be further investigated in different geographic settings. In general, these insights will support identification of groups at increased risk and targeted public health actions such as intensified screening, 3-site testing using molecular diagnostics, sexual contact tracing, and surveillance of treatment failures.es_ES
dc.description.sponsorshipThe study was funded by the ECDC (Framework Contract No. ECDC/2017/004). Open Access funding provided by Örebro Universityes_ES
dc.language.isoenges_ES
dc.publisherBioMed Central (BMC) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectGonorrhoeaes_ES
dc.subjectCeftriaxonees_ES
dc.subjectAzithromycines_ES
dc.subjectAntimicrobial resistancees_ES
dc.subjectSurveillancees_ES
dc.subjectEuropean Gonococcal Antimicrobial Surveillance Programme (Euro-GASP)es_ES
dc.subjectEuropees_ES
dc.subject.meshDrug Resistance, Bacterial es_ES
dc.subject.meshSex Factors es_ES
dc.subject.meshSexual and Gender Minorities es_ES
dc.subject.meshAnti-Bacterial Agents es_ES
dc.subject.meshAzithromycin es_ES
dc.subject.meshCefixime es_ES
dc.subject.meshCeftriaxone es_ES
dc.subject.meshCiprofloxacin es_ES
dc.subject.meshEuropean Union es_ES
dc.subject.meshFemale es_ES
dc.subject.meshGonorrhea es_ES
dc.subject.meshHeterosexuality es_ES
dc.subject.meshHomosexuality, Male es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMale es_ES
dc.subject.meshMicrobial Sensitivity Tests es_ES
dc.subject.meshNeisseria gonorrhoeae es_ES
dc.subject.meshSexual Behavior es_ES
dc.titleAssociations between antimicrobial susceptibility/resistance of Neisseria gonorrhoeae isolates in European Union/European Economic Area and patients' gender, sexual orientation and anatomical site of infection, 2009-2016es_ES
dc.typeresearch articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID33736608es_ES
dc.format.volume21es_ES
dc.format.number1es_ES
dc.format.page273es_ES
dc.identifier.doi10.1186/s12879-021-05931-0es_ES
dc.contributor.funderUnión Europea. European Centre for Disease Prevention and Control (ECDC) es_ES
dc.contributor.funderÖrebro University (Suecia)es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1471-2334es_ES
dc.relation.publisherversionhttps://doi.org/10.1186/s12879-021-05931-0es_ES
dc.identifier.journalBMC infectious diseaseses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional